AdvertisementSupported byBusiness BriefingBy The Associated PressFor the first time, there is evidence that a drug reduces the risk of complications that are the top killer of diabetes patients: heart attacks, strokes and other cardiovascular damage. The makers of Jardiance — Eli Lilly and its partner, Boehringer Ingelheim — are releasing limited data from a 7,000-patient study indicating their year-old drug delayed the time until patients died of cardiovascular disease or suffered a heart attack or stroke. That has been a long-elusive goal for diabetes patients and their doctors. While diabetes pills and insulin help control blood sugar and sometimes weight, none until now have been shown to reduce cardiovascular complications. Advertisement